the sla story today

Put simply SLA is in my opinion an extremely undervalued stock. The potential SLA has is way beyond the current SP.

The timing of the ANZ debacle was extremely unfortunate for the company, but fortunate for shareholders if you got in at these low prices.

SLA was at the EDGE of transition from a pure R&D biotech to a significant revenue producer. This is evidenced by the SibeX production facility finally in function.. thats right.. THEY ARE IN PRODUCTION!!

SLA was sitting comfortably above $1 pending approval of Ropren .. and the next jump was weeks away (from Ropren pricing annoucnment), until OPES Prime hung a stinker. Since then it has been downhill as far as SP is concerned.. but were now back ... and things have been moving along at SLA.. albeit some delays due to ANZ.. but were on track again.. thats the key

Now if you know anything about the market... this is the best time to receive a great return/risk. In short this is the best time to get on SLA.. i.e. before the big boys take notice and put SLA on their portfolios.

Some things to note...


- BioR aka Ropren (final regulatory approval received (price was at $1.30))

Duel Target Markets: Alzhemier's disease suffers (billion$ global market), and liver disease (see alcoholics trial).

The Ropren path so far:
clinical trials (completed in late 2004)
pharmacological approval (received in Feb 2006), finally pharmaceutical approval (received!), production begins in Tomsk site ..

whats next? sales sales and $$$ ! At approx $2k a pop .. and with several hospitals already lined up to purchase Ropren ... and the strong Govt support received thus far (I believe a subsidy will be in place for Ropren purchases? - need to be confirmed).


- The vehicle to produce = SibeX acquisition (complete)
- Whats next is the facility upgrade which is to be completed in a few stages.. the major one to come next year!


==So what is all the fuss about on Ropren??==

***Ropren has been proven (through clinical trials) to be a side-effect free treatment for chronic liver disease and in regenerating liver tissue. It has a multi-facet ability to also treat neurodegenerative disorders (alzheimers) and stabilise cholesterol levels. These additional uses have not been as well tested as the liver cell regeneration .. but there have been marked improvements in those two areas through the trials. Time will tell.

*** Animal husbandry (Bioprospect deal -recent TH) - significance of bioeffectives will be realised through this deal with BPO. Essentially SLA want to concentrate on the benefits to 'humans' and have outsourced the animal/agricultrual benefits to BPO (we still get a good cut of the profits)

*** 15+ bioeffectives have been developed by SLA. SLA are only concentrating on a few at the moment, but all have multiple uses and huge potential. Ropren is only the beginning for SLA. THE BEGINNING!!

== SLA cash position==
$4.3m in bank as at July08 i.e. no cap raising in sight.

==SLA awareness==
European Gastroenterology Conference being held in May 07 significantly boosted Ropren's awareness in Russia. The 08 conference (not sure when it was/is held) .. is to gauge the level of demand of Ropren in the coming years.. the difference from 07 and 08.. is that in 08 production would have already started .. with a plant upgrade and acquisition in the pipeline. Remember these conferences are where ground breaking products are announced.. and the world does take notice.


Market cap of SLA is around AU$50m. Ropren in itself is expected to generate US$50m a year within 3 years of release. Ropren is but one of many products SLA have in the pipe-line.

Remember the smart money gets in when the people who bought on the hype sell off. You know the saying buy low sell high? This is how you do it. The rise from 28c to 38c is only the beginning .. 2 yrs ago.. sla was at 32c.. and within 6 months it was $1.30. What is needed to pust SLA above $1.30 is $$$.. thats right revenue.. and thats what were waiting on.. and sales are expected to start soon.. if not already in Russia. Look out for that.


There is no substitute to research.. so go off and do some.